Project Grant R01CA294071
Award Date
9/19/24
Completion Date
8/31/29
Dollars Obligated
$653K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The federal Project Grant award R01CA288535, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of novel cellular therapies to treat highly malignant brain tumors known as glioblastomas (GBMs). Awarded to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, the $417,858 grant will enable the research team to engineer mesenchymal stem cells (MSCs) to release bi-specific T cell engager (BiTE)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $645,873 to The University of Texas MD Anderson Cancer Center to develop an innovative in vivo approach for generating chimeric antigen receptor (CAR) macrophages targeting the epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma immunotherapy. The 5-year project, beginning in July 2024, aims to evaluate the dynamics, safety, transcriptional profiles, and...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $627,061 in funding to The General Hospital Corporation (Massachusetts General Hospital) to develop and evaluate oncolytic herpes simplex virus (oHSV) immunotherapies for the treatment of glioblastoma (GBM), a deadly form of brain cancer. The key products and services to be delivered include: In vitro testing of oHSV variants engineered to express IL-12 and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,831 to the University of Colorado-Denver to develop chimeric antigen receptor (CAR) phagocytes as a novel treatment for glioblastoma, a highly aggressive type of brain cancer. The 5-year project aims to investigate the use of engineered immune cells to target and eliminate glioblastoma tumors, with a focus on pediatric high-grade gliomas. The research will explore the potential...
The National Cancer Institute awarded Dartmouth College a $604,627 Project Grant under the Cancer Biology Research (CFDA 93.396) program to study ways to engineer durable antitumor protection using chimeric antigen receptor (CAR) T cell therapies. The project aims to deconvolve CAR T cell heterogeneity to understand how individual T cell subsets behave in vivo and identify engineering strategies to program CAR stem cell-like (TSCM) and tissue-resident memory (TRM) cell fates. This research could...
The National Cancer Institute awarded a $701,408 Project Grant (CFDA 93.395 Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on enhancing the response to immune checkpoint blockade therapy in central nervous system metastases from breast cancer. The project aims to characterize mechanisms of resistance to immunotherapy in central nervous system metastases by profiling cancer and immune cells using...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research to enhance the antitumor activity of chimeric antigen receptor (CAR) T-cell therapy for renal cell carcinoma. The $297,728 grant, awarded on July 1, 2024, will fund the targeted delivery of a VEGF-blocking single-chain variable fragment (scFv) by CD70 CAR-T cells to modulate the tumor microenvironment and prevent CAR-T cell exhaustion. The research,...
The federal Project Grant award R01CA291826, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is funding the development of GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid and sensitive molecular subtyping of gliomas. The total funding amount is $678,228, with the award starting on April 3, 2025 and a targeted completion date of March 31, 2030. The key products and services to be delivered under this...
The U.S. National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $620,820 Project Grant (CFDA 93.396 - Cancer Biology Research) to investigate CREB5-driven mechanisms of immune therapy resistance in cancer. The key objectives are to: 1) understand the molecular mechanisms governing CREB5 regulation and transcription; 2) identify CREB5-interacting proteins that drive collagen matrix deposition; and 3) elucidate how...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen for the treatment of acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3) evaluate the safety of the MR1 CAR-T cells. This work...